FTC and Four States Sue WPATH Over Transgender Healthcare Guidelines

The Federal Trade Commission, joined by four Republican-led states, has launched an unprecedented legal strike against the world’s leading transgender health organization. Filed in a federal court in Fort Worth, Texas, the lawsuit accuses the World Professional Association for Transgender Health (WPATH) of deceiving parents and patients about the safety and efficacy of gender-affirming care for minors. The complaint marks a significant escalation in the Trump administration’s broader campaign to restrict pediatric medical transitions, shifting the battlefield from state legislatures to federal consumer protection law. By targeting the nonprofit organization responsible for the clinical guidelines used by doctors and insurers worldwide, the federal government is attempting to dismantle the institutional foundation of transgender healthcare in the United States.[1][2][4]

At the heart of the 123-page complaint is the allegation that WPATH’s widely adopted "Standards of Care" function as deceptive marketing. The FTC, alongside the attorneys general of Alaska, Iowa, Nebraska, and Texas, claims the organization overstated the benefits of puberty blockers, hormone therapies, and surgeries—specifically their role in reducing suicide risk among youth experiencing gender dysphoria. Furthermore, the plaintiffs allege WPATH deliberately minimized or omitted the lifelong medical risks and side effects of these treatments. The lawsuit contends that by mischaracterizing the medical evidence, WPATH duped consumers into purchasing medical services, thereby allowing its member clinicians to profit in violation of the FTC Act and state consumer protection laws.[1][3][7]

FTC Chairman Andrew N. Ferguson framed the litigation strictly as a consumer protection mandate, asserting that parents require complete and truthful information when making irreversible medical decisions for their children. Ferguson stated that the agency will not permit medical organizations to prioritize profit over pediatric health and safety. The lawsuit leans heavily on a November 2025 report from the U.S. Department of Health and Human Services, commissioned under a Trump executive order, which concluded that the evidence supporting pediatric gender-affirming services is weak or inconclusive. The plaintiffs are asking a federal judge to grant a permanent injunction against WPATH, blocking future alleged violations, and are seeking civil penalties and monetary relief for the involved states.[3][5][7]

WPATH has forcefully rejected the allegations, characterizing the lawsuit as a politically motivated abuse of federal power designed to intimidate medical professionals and harm transgender patients. In a public statement, the organization defended its half-century history of developing guidelines based on established scientific standards, expert consensus, and individualized patient care rather than a "one size fits all" approach. WPATH argued that the FTC, which is not a medical provider or regulator, has no jurisdiction over the organization's noncommercial speech or clinical recommendations. The group accused the federal government of acting out of "pure retaliation" as part of a relentless campaign to undermine evidence-based gender-affirming care.[2][4][6]

Legal and public health observers note that the lawsuit represents a massive and highly unusual expansion of the FTC’s traditional authority. Lawrence Gostin, an international public health expert at Georgetown University, pointed out that the agency is leveraging consumer protection statutes to second-guess the scientific justifications of a professional medical association's clinical guidelines. Historically, the FTC has targeted companies making false claims about dietary supplements or miracle cures, not the foundational standards of care endorsed by mainstream medical bodies like the American Medical Association and the American Academy of Pediatrics. Critics warn that this approach could set a chilling precedent, allowing federal regulators to police scientific debate and medical consensus whenever it conflicts with an administration's political agenda.[1][6]

The lawsuit arrives just weeks after WPATH secured a preliminary victory against the FTC in a related dispute. In May 2026, Chief U.S. District Judge James Boasberg in Washington, D.C., temporarily blocked the FTC from enforcing civil investigative demands against WPATH and the Endocrine Society. The judge ruled that the organizations were likely to succeed in proving that the FTC’s probe was retaliatory and violated their First Amendment rights to free speech and scientific inquiry. WPATH cited that prior ruling in its defense this week, expressing confidence that the courts will again recognize the administration's actions as an unconstitutional overreach aimed at suppressing protected medical speech.[4][5]

The stakes of the Fort Worth litigation extend far beyond WPATH itself. Because the organization’s Standards of Care are the benchmark used by most major insurance companies to determine the medical necessity of pediatric transition services, a federal ruling discrediting those guidelines could trigger a cascade of coverage denials nationwide. It could also expose individual pediatricians and clinics to heightened legal liability and consumer fraud lawsuits, even in states that legally protect gender-affirming care. The lawsuit explicitly credits WPATH’s recommendations for the significant increase in children being medically transitioned in recent years, making the organization a prime target for conservative lawmakers seeking to reverse that trend.[2][3]

This legal maneuver is the latest front in a sweeping effort by the Trump administration to restrict transgender healthcare access since returning to office. Following Executive Order 14187 in January 2025, which directed federal agencies to cease supporting pediatric gender-affirming care, the administration has utilized various federal levers—from HHS funding threats to Department of Justice probes—to curb the practice. As the FTC lawsuit moves forward in a Texas federal court known for its amenability to conservative legal challenges, the outcome will likely shape the future of medical autonomy, the boundaries of consumer protection law, and the daily lives of hundreds of thousands of transgender youth and their families across the country.[3][4][6]